卡瑞丽珠单抗联合紫杉醇+顺铂治疗晚期食道癌的临床效果分析  

Clinical Effect of Carrilizumab Combined with Paclitaxel and Cisplatin in the Treatment of Advanced Esophageal Cancer

作　　者：王菁菁 刘江 蒋平 WANG Jingjing;LIU Jiang;JIANG Ping(Department of Oncology,Xinghua People's Hospital,Xinghua,Jiangsu Province,225700 China)

机构地区：[1]兴化市人民医院肿瘤科,江苏兴化225700

出　　处：《中外医疗》2024年第10期82-85,共4页China & Foreign Medical Treatment

摘　　要：目的探讨卡瑞丽珠单抗联合紫杉醇和顺铂对晚期食道癌的临床疗效。方法随机选取2020年1月—2022年12月兴化市人民医院收治的80例晚期食道癌患者为研究对象,运用随机数表法分为观察组(紫杉醇+顺铂+卡瑞丽珠单抗;n=40)和对照组(紫杉醇+顺铂;n=40),比较两组临床效果、不良反应、生活质量评分。结果观察组患者的治疗总有效率为95.00%,明显高于对照组的80.00%,差异有统计学意义(χ^(2)=4.114,P<0.05)。观察组患者的不良反应发生率为5.00%,明显低于对照组的20.00%,差异有统计学意义(χ^(2)=4.114,P<0.05)。观察组生活质量评分显著高于对照组,差异有统计学意义(P<0.05)。结论卡瑞丽珠单抗联合紫杉醇和顺铂对晚期食道癌具有显著的临床疗效。与单纯紫杉醇和顺铂治疗相比,联合治疗可提高治疗有效率,降低不良反应发生率,并提高患者的生活质量。因此,卡瑞丽珠单抗联合紫杉醇和顺铂可作为晚期食道癌的优选治疗方案。Objective To investigate the clinical efficacy of carrilizumab combined with paclitaxel and cisplatin in the treatment of advanced esophageal cancer.Methods Eighty patients with advanced esophageal cancer admitted to the Xinghua People's Hospital from January 2020 to December 2022 were randomly selected as the study objects,and divided into observation group(paclitaxel+cisplatin+karelizumab;n=40)and control group(paclitaxel+cisplatin;n=40)by random number table method.Clinical outcomes,adverse reactions,and quality of life score were compared between the two groups.Results The effective rate of observation group was 95.00%,significantly higher than that of control group 80.00%,and the difference was statistically significant(χ^(2)=4.114,P<0.05).The incidence of adverse reactions in observation group was 5.00%,significantly lower than that in control group 20.00%,and the difference was statistically significant(χ^(2)=4.114,P<0.05).The quality of life score in observation group was significantly higher than that of the control group,and the difference was statistically significant(P<0.05).Conclusion Carrilizumab combined with paclitaxel and cisplatin has a significant clinical effect on advanced esophageal cancer.Compared with paclitaxel and cisplatin alone,combination therapy can increase the effective rate of treatment,reduce the incidence of adverse reactions,and enhance the quality of life of patients.Therefore,carrilizumab combined with paclitaxel and cisplatin may be the preferred treatment for advanced esophageal cancer.

关 键 词：卡瑞丽珠单抗 紫杉醇 顺铂 晚期食道癌 

分 类 号：R4[医药卫生—临床医学]